tradingkey.logo
tradingkey.logo
Search

BioArctic says Rolling Sbla Initiated To U.S. FDA For Leqembi® Iqlik™ As Subcutaneous Starting Dose For Early Alzheimer's Disease Treatment Under Fast Track Status

ReutersSep 3, 2025 3:04 AM
facebooktwitterlinkedin

- BioArctic AB BIOAb.ST:

  • ROLLING SBLA INITIATED TO THE U.S. FDA FOR LEQEMBI® IQLIK™ (LECANEMAB-IRMB) AS A SUBCUTANEOUS STARTING DOSE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE UNDER FAST TRACK STATUS

Further company coverage: [BIOAb.ST]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI